Quality & complianceCompany release

USFDA closes Dr. Reddy's Bachupally FTO-3 inspection with Voluntary Action Indicated status

Dr Reddys Laboratories Ltd (RDY) · Mon 16 Nov 2026

Dr. Reddy's says the US regulator has classified its Hyderabad formulations plant inspection as VAI and considers the inspection officially closed.

Dr. Reddy's Laboratories has told Indian and US stock exchanges that the US Food and Drug Administration classified the GMP inspection of its FTO-3 formulations facility in Bachupally, Hyderabad, as Voluntary Action Indicated (VAI). The company made the disclosure on 14 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Dr Reddys Laboratories Ltd ↗

Article written by VigiEye from the official source (Dr Reddys Laboratories Ltd). Claims are the company's own. AI-assisted; check the source before acting.